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PENYIASATAN TEKNIK-TEKNIK PENUTUPAN RASA DAN 




Dalam pembangunan tablet terkecai oral (ODT), kesedapan memainkan 
peranan yang penting. Oleh kerana kajian mengenai penutupan rasa drug yang 
menyebabkan kepedihan mukosa mulut dan rasa pahit adalah amat jarang, 
dapoxetine HCl dipilih untuk kajian ini. Pelbagai teknik penutupan rasa telah dikaji 
termasuk pembentukan kompleks dengan resin penukaran ion, penyalutan dengan 
polimer sensitif pH, penyalutan dengan polimer hidrofilik, pengubahsuaian kimia, 
penambahan pemanis dan perisa, pembentukan kompleks inklusi dan penjerapan 
dengan sebatian bukan organik. Pembentukan kompleks dengan resin penukar ion 
(Kyron T-134) telah didapati sebagai teknik penutupan rasa terbaik dengan 
pembentukan kompleks drug-resin yang tidak larut di dalam rongga mulut. Dalam 
pembangunan ODT, pengeringanbekuan, acuan pelakuran, peralihan fasa dan teknik 
pemampatan langsung telah dikaji. Dalam teknik pengeringanbekuan, kesan polimer 
(hidroksipropil metilselulosa (HPMC), Carbopol 934P dan Eudragit®  EPO) dan 
kanji gandum, ke atas sifat-sifat fizikal ODT dikaji. Peningkatan kepekatan polimer 
dan kanji gandum meningkatkan kekerasan dan masa pengecaian ODT. ODT yang 
terdiri daripada HPMC dan kanji gandum dengan kekerasan 0.86 ± 0.04 kg dan masa 
pengecaian in-vitro 166,67 ± 4.32 s telah diperolehi. Dalam teknik acuan pelakuran, 
mentega koko digunakan sebagai matriks. Penambahan PEG 6000 dan lilin lebah 
meningkatkan kekerasan dan masa pengecaian ODT. Sebaliknya, penambahan kanji 
jagung meningkatkan kekerasan tetapi mengurangkan masa pengecaian ODT. 
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Pengecaian yang cepat dicapai melalui peleburan matriks mentega koko dan 
pengembangan kanji jagung, yang mengganggu integriti matriks tablet. ODT yang 
mempunyai kekerasan dan masa pengecaian in-vitro 2.93 ± 0.22 kg dan 151.67 ± 
6.98 s telah dihasilkan. Untuk teknik peralihan fasa pula, tiga gula alkohol bertakat 
lebur tinggi (mannitol, maltitol dan erythritol) dan takat lebur rendah (xylitol, 
trehalose dan sorbitol) telah dikaji. Gabungan mannitol dan trehalose didapati 
optimum dengan nilai kekerasan 8.81 ± 0.18 kg dan masa pengecaian in-vitro 167.17 
± 3.87 s. Takat lebur gula alkohol yang rendah bertindak sebagai pengikat 
meningkatkan keluasan permukaan ikatan antara zarah dan meningkatkan kekerasan 
ODT. Masa pengecaian in-vitro ODT yang dihasilkan dengan menggunakan tiga 
teknik yang dihuraikan adalah lebih kurang 3 minit. Pemampatan langsung adalah 
kaedah yang mudah, cepat dan lebih murah. Penggunaan adjuvan ko-pemprosesan 
yang boleh dimampat dengan sifat pengecaian cepat adalah salah satu cara untuk 
menangani cabaran teknik pemampatan langsung. Empat jenis “superdisintegrants” 
iaitu, natrium kanji glycolate, natrium croscarmellose, crospovidone XL-10 dan 
natrium polacrilin (Kyron T-314), telah dikaji. Gabungan Kyron T-314 
(pengembangan) dan crospovidone XL-10 (kesan kapilari) didapati sebagai 
kombinasi yang optimum untuk mencapai pengecaian terpantas. Adjuvan ko-
pemprosesan yang terdiri daripada natrium polacrilin (Kyron T-314), crospovidone 
XL-10, mannitol dan selulosa mikrokristalin, telah dihasilkan dengan menggunakan 
kaedah granulasi basah, dan digunakan untuk menghasilkan ODT penutupan rasa 
dapoxetine dengan kekerasan dan masa pengecaian 6.77 ± 0.38 kg dan 58.00 ± 3.85 
s masing-masing. Kesimpulannya, pembentukan kompleks dengan resin penukaran 
ion (Kyron T-134) didapati  teknik terbaik dan pemampatan langsung menggunakan 
adjuvan ko-pemprosesan yang terdiri daripada natrium polacrilin (Kyron T-314), 
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Crospovidone XL-10, mannitol dan mikrokristalin selulosa, adalah kaedah 
pembuatan yang diingini. Penemuan dalam penyelidikan ini boleh menyumbang 



























INVESTIGATION OF TASTE MASKING TECHNIQUES AND 





In the development of orally disintegrating tablets (ODT), palatability plays a 
critical role.  As there were hardly any reported studies on taste masking of drugs 
which cause burning sensation on oral mucosa and is bitter in taste, dapoxetine HCl 
was chosen for the study. Various taste masking techniques, namely complex 
formation with ion exchange resin, coating with pH sensitive polymer, coating with 
hydrophilic polymer, chemical modification, addition of sweetener and flavour, 
inclusion complexation and blending with inorganic compound, were investigated. 
Complex formation with ion exchange resin (Kyron T-134) was found to be the best 
taste masking technique by formation of insoluble drug-resin complex in the oral 
cavity. In the development of ODT, lyophilisation, fusion moulding, phase transition 
and direct compression techniques were investigated. In the lyophilisation technique, 
the effect of  polymers (hydroxypropyl methylcellulose (HPMC), Carbopol 934P and 
Eudragit®  EPO) and wheat starch, on the physical properties of lyophilized ODT was 
studied.  Increasing the concentration of polymers and starch increased the hardness 
and disintegration time of ODT. ODT comprising HPMC and starch with hardness 
of 0.86 ± 0.04 kg and in-vitro disintegration time of 166.67 ± 4.32 s was obtained. In 
the fusion moulding technique, cocoa butter was used as the matrix. Addition of 
PEG 6000 and beeswax increased the hardness and disintegration time of ODT. On 
the other hand, addition of corn starch increased the hardness but reduced the 
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disintegration time of ODT. Faster disintegration was achieved through melting of 
cocoa butter and swelling of corn starch, leading to the disruption of tablet integrity. 
The ODT tablet with hardness and in-vitro disintegration time of 2.93 ± 0.22 kg and 
151.67 ± 6.98 s was produced. For phase transition technique, three high melting 
point (mannitol, maltitol and erythritol) and low melting point (xylitol, trehalose and 
sorbitol) sugar alcohols were studied. The combination of mannitol and trehalose 
was found to be optimum with hardness value of 8.81 ± 0.18 kg and in-vitro 
disintegration time of 167.17 ± 3.87 s. The low melting point sugar alcohol acted as 
binder increasing the bonding surface area between particles, enhancing the hardness 
of ODT. The in-vitro disintegration time of the ODT produced using the three 
techniques was approximately 3 min. Direct compression is a relatively simple, rapid 
and more economical method. The use of co-processed adjuvant that was 
compressible with fast disintegration characteristic was one of the means to 
circumvent the challenges of direct compression technique. Four types of 
superdisintegrants namely, sodium starch glycolate, croscarmellose sodium, 
Crospovidone XL-10 and polacrilin potassium (Kyron T-314), were studied. 
Combination of Kyron T-314 (swelling) and crospovidone XL-10 (wicking) was 
found as the optimum combination to achieve the fastest disintegration. Co-
processed adjuvant consisting of polacrilin potassium (Kyron T-314), Crospovidone 
XL-10, mannitol and microcrystalline cellulose, was prepared using wet granulation 
method, and used to produce taste masked dapoxetine ODT with hardness and in-
vitro disintegration time of 6.77 ± 0.38 kg and 58.00 ± 3.85 s. In conclusion, 
complex formation with ion exchange resin (Kyron T-134) was found to be the best 
taste masking technique and direct compression using a newly developed co-
processed adjuvant consisting of polacrilin potassium (Kyron T-314), Crospovidone 
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XL-10, mannitol and microcrystalline cellulose, was the preferred manufacturing 
method. The findings in this current research could contribute to the advancement in 





  INTRODUCTION 
 
1.1 Background of orally disintegrating tablet  
Oral drug delivery remains the most popular route of drug delivery (Sudhir et al., 
2010). It is because oral drug delivery system has the key advantage of convenient 
administration. Tablets and hard gelatin capsules constitute a major portion of 
drug delivery systems that are currently available due to its convenience of self 
administration, compactness and simple manufacturing process. Moreover, drug is 
found to be more stable in solid dosage form than liquid dosage form. However, 
many patients experience the fear of swallowing tablets and capsules. Some 
patients have experienced choking while taking tablets or capsules of large size. 
As a result, they do not take their medication as prescribed and non-compliance 
issues arise. Honda and Nakano (1998) conducted a survey and found that half of 
patients experienced difficulty in taking solid medications such as tablets and 
capsules, which resulted in a high incidence of non-compliance and ineffective 
therapy. Majority of patients who are found to be non-compliant to the treatment 
are paediatric and geriatric populations (Seager, 1998). The mentally retarded and 
un-cooperative, nauseated or on reduced liquid-intake/diet patients, have 
difficulties swallowing these dosage forms. Patients who travel or have little 
access to water are similarly affected (Hanawa et al., 1995). 
 
Orally disintegrating tablets (ODTs) are also known as orodispersible tablets, 
mouth dissolving tablets, fast melt tablets, rapid dissolving tablets and quick 
dissolving tablets (Hirani et al., 2009). ODT systems came into existence in the 
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late 1970’s as an alternative to tablets and capsules for pediatric and geriatric 
patients who experience difficulties in swallowing traditional oral solid dosage 
forms (Hanawa et al., 1995).  
 
Orally disintegrating tablets (ODT) are different from chewable tablets and 
effervescent tablets. Chewable tablets are not practical for patients suffering from 
mouth ulcer or have difficulty in chewing or painful oral cavity. On the other hand, 
effervescent tablet requires water to dissolve the tablet which might not be 
available in some situations such as during traveling (Mizumoto et al., 2005).   
 
Bradoo (2001) listed a few ideal characteristics that ODTs should have. The ODT 
should 
a. disintegrate in mouth in a matter of seconds. 
b. be taken directly without requires the access to water due to its fast 
disintegrating property. 
c. employ effective taste masking technique. 
d. have pleasant mouth feel. 
e. be robust and less friable. 
f. be stable. 
g. have simple manufacturing method which can use conventional 
processing and packaging equipment. 
h. allow high drug loading. 




Kuchekar et al. (2003) listed some of the advantages of ODTs over other dosage 
forms: 
a. ODT is a patient friendly dosage form; it reduces the risk of choking 
and eliminates the fear of swallowing tablets. 
b. convenient in administration as water access is not a must. 
c. accurate and precise dosing as compared to liquids. 
d. rapid disintegration of the dosage form that speeds up the dissolution 
of drug and absorption, leading to rapid onset of pharmacological 
action. 
e. convenient for administration and improved patient compliance 
especially for geriatric, pediatric, disabled and bedridden patients.  
 
1.2 Patient’s preference  
Patient preference is an important factor in long-term treatment adherence and 
thus treatment outcome (Jahng et al., 2005). A survey revealed that almost half of 
the patients prefer ODTs to other dosage forms (Deepak, 2004) and about 70% 
respondents would ask their doctors for ODTs if they are given a choice. Around 
70% patients would choose to purchase ODT products and 80% respondents 
indicated that they prefer ODT products than regular tablet or liquid dosage forms 
(Brown, 2003). There was another survey carried out by Kinon et al (2003) on the 
preference of patients on olanzapine ODT and conventional tablet using the 
Patient Global Impression Scale (1- I like it very much; 7 - I dislike it very much). 
The average score for the ODT product was in the range of 2.01 – 2.74, signifying 
a positive acceptance of the product at all measured time points. Bitter et al. 
(2010) investigated the preference of patients on oral olanzapine formulation by 
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comparing patients’ preference for ODT versus conventional tablet in a 
randomized open-label crossover study. Overall, 61% of patients preferred ODT 
and only 27% preferred conventional tablets while 12% expressed no preference. 
 
1.3 Problem statement 
ODT is a novel oral drug delivery system which offers added advantages over 
conventional dosage forms such as ease of administration, elimination of fear of 
choking and faster pharmacological onset. However, there are certain challenges 
in the development of ODT, which include rapid and cost effective processing 
method, satisfactory palatability, rapid disintegration time, and stability. The ODT 
inventions in the market disintegrate mainly through porous and weak tablet 
matrix, swelling and wicking of disintegrant. The mechanical strength and 
hardness of ODT are often compromised to achieve rapid disintegration. Special 
packaging is needed to protect the product integrity which results in an increase in 
overall production cost. 
 
Dapoxetine HCl is a drug candidate which causes burning sensation on oral 
mucosa and is bitter in taste. Up-to-date, there is hardly any study on taste 
masking techniques for drugs causing burning sensation on oral mucosa. As such, 
present research could generate new knowledge in the field of orally 
disintegrating drug delivery systems.  
 
Dapoxetine HCl in the form of ODT has not yet been available commercially. 




Effective taste masking techniques to improve palatability of drug candidate 
causing burning sensation in oral cavity and amicable manufacturing methods of 
ODT are crucial to contribute to the success of ODT.   
 
1.4 Experimental work and scope of study  
The study was performed in various stages encompassing the following 
objectives: 
1. To investigate the various taste masking techniques to improve the 
palatability of dapoxetine HCl 
2. To develop  orally disintegrating tablets using  
a. lyophilization technique and investigation of the effects of polymers 
and starch on the physical properties of lyophilized ODT 
b. fusion moulding technique and investigation of the effects of waxes, 
starch and PEG 6000 on the development of cocoa butter based ODT  
c. phase transition technique and characterization of ODT  
d. direct compression technique and development of novel co-processed 
adjuvant   
3. To develop and validate bioanalytical LC-MSMS assay method to 










 LITERATURE REVIEW 
 
2.1 Taste masking  
Taste refers to a perception arising from the stimulation of taste buds present on 
the surface of the tongue. Humans can distinguish the components of taste: 
sourness, saltiness, sweetness and bitterness (Ayenew et al., 2009). Taste masking 
technology is used in development of orally disintegrating dosage forms, as 
majority of drugs are bitter in nature. When the dosage form disintegrates in the 
mouth, the taste bud is exposed to the bitter drug. 
 
Hitherto, various taste masking technologies have been developed to address the 
problem of patient compliance. Below is the summary of some taste masking 
technologies used in the formulation of orally disintegrating dosage forms. 
 
2.1.1 Taste masking strategies 
Most of the active pharmaceutical ingredients have poor taste and bad mouth feel. 
Some might even cause irritation and burning sensation on the tongue. Effective 




Coating is suitable for very bitter drug molecules. It is an efficient way to prevent 
the bitter molecules from being in direct contact with the taste buds. Hydrophobic 
polymers, lipids, sweeteners and hydrophilic polymers are common coating 
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materials. Roche et al. (1993) reported taste masked famotidine formulated using 
a combination of water soluble polymer (polyvinylpyrrolidone) and water 
insoluble polymer (cellulose acetate) as the coating material. Yeong et al. (2003) 
described the wet granulation of a mixture of pivoxil sulbactam and stearic acid 
with ethanolic solution of polyvinylpyrrolidone, followed by coating with 
colloidal silicon dioxide in a high speed rotary mixer to achieve taste masking. 
Granules containing ibuprofen, polyvinylpyrrolidone, sodium starch glycolate and 
sodium lauryl sulphate, were coated with hydroxyethyl cellulose and a mixture of 
hydroxyethyl cellulose and hydroxypropyl methylcellulose, to achieve taste 
masking. However, coating of drugs might retard the dissolution process in 
certain cases. Choosing the appropriate coating material is important so that the 
new formulation is bioequivalent with the original formulation (Fu et al., 2004).  
 
2.1.1(b) Granulation 
It is an economical, practical and rapid process, which most industries are 
affordable to apply.  Wet granulation can be used to mask the bitter taste of drugs. 
Granulation can be formed by mixing the bitter medicament, with sweeteners, 
hydrophobic polymers, lipids or waxes.  
 
Liquid and low melting point waxes such as glycerol palmitostearate, glyceryl 
behenate and hydrogenated castor oil are commonly used ingredients during the 
granulation to achieve taste masking (Ayenew et al., 2009).  
 
Bertelsen et al. (2006) described the melt granulation to achieve the taste masking 
of calcium carbonate. The method involved a melt granulation process where a 
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sugar alcohol was melted in which calcium-containing compound was embedded 
to mask the chalkiness and unpleasant mouth feel of the calcium-containing 
compound. 
 
2.1.1(c) Addition of sweetener and flavor 
This is a simple taste masking method that can be used alone or in combination 
with other strategies to achieve better taste masking. The use of synthetic 
sweeteners such as saccharine sodium, aspartame and sucralose are common in 
most taste masked products. Although artificial sweeteners have an intense 
sweetness, they leave a bitter or metallic after taste, which cause non-compliance 
in patients. To solve this problem, artificial sweeteners were used in combination 
with sugar alcohols such as lactitol, maltitol and sorbitol, to decrease the after-
taste of artificial sweeteners. Sucralose can be used with physiologically 
acceptable acids (e.g. citric acid) to increase the taste masking efficiency of the 
sweetener. More recently, newer sweeteners derived from plant parts have been 
evaluated for taste masking efficiency. For example, stevia was used to prepare 
taste masked ibuprofen (Roche et al., 1993). Ammonium glycyrrhizinate which is 
extracted from glycyrrhiza root and is 50-60 times sweeter than sucrose is used in 
the food industry (Couteau and Coiffard, 2001). 
 
2.1.1(d) Microencapsulation 
Microencapsulation is a process by which very tiny droplets or particles of liquid 
or solid material are surrounded or coated with a film or polymeric material 





• Taste masking can be achieved with the desirable controlled drug release. 
• Bitter liquids may be coated to convert them to solid particles. 
•The coated bitter particles can adapt to a wide variety of dosage forms and 
product applications. 
 
The goal of microencapsulation may be accomplished by any of the following 
techniques: 
• Air suspension coating 
• Coacervation-phase separation 
• Spray drying and spray congealing 
• Solvent evaporation 
• Multiorifice-centrifugal process 
• Pan coating 
• Interfacial polymerisation 
 











Table 2.1: Taste masking by microencapsulation techniques reported in 
literature.  
 










































































2.1.1(e) Taste suppressant and potentiator 
Bitter blockers such as adenosine monophosphate are a group of compounds 
which compete with bitter substances to bind with G-protein coupled receptor 
(GPCR) sites (Margolskee and Ming, 2003). In general, binding of the bitter 
substance to the receptor causes the sensation of bitterness on the tongue. 
Lipoproteins are universal bitter taste blockers. Venkatesh and Palepu (2002) 
described the application of taste suppressants like phospholipid (BMI-60) in taste 
masking of bitter medicaments. Potentiators increase the perception of the taste of 
sweeteners and mask the unpleasant taste. Various potentiators include thaumatin, 
neohesperidine dihydro chalcone (NHDC) and glycyrrhizin can increase the 
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perception of sodium or calcium saccharinates, saccharin, acesulfame and 
cyclamates (Abraham and Mathew, 2014). The various taste suppressants and 
potentiators used for taste masking reported by other researchers are presented in 
Table 2.2. 
 
Table 2.2: Taste masking by taste suppressant / potentiator reported in 
literature. 
 
Drug Category Taste 
suppressant/potentiator used 
Reference 
Bromhexine Mucolytic Thaumatin and sugar Scheuring et 
al., 2013 
Caffeine Diuretic Hydroxyflavones Ley et al., 
2012 
Caffeine Diuretic Gamma-amino butyric acid Kardos and 
Blandl, 1994 
Paracetamol Antipyretic Potentiators: glycyrrhizin, 
thaumatin, and neohesperidine 
dihydro chalcone 






2.1.1(f) Ion exchange resin 
Ion exchange resins can be used as a method to mask the taste of a bitter 
molecule. They are high molecular weight polymers with cationic and anionic 
functional groups. Sudhakar et al. (2007) reported a method using polacrilin resin 
(porous copolymer of methacrylic acid crosslinked with divinyl benzene) to mask 
bitter taste of drugs such as cetirizine dihydrochloride and levocetirizine. A wet 
granular mass of drug with cationic resin was prepared. The dried granules were 
mixed with mannitol, crospovidone, microcrystalline cellulose and magnesium 
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stearate to form directly compressed chewable tablets. Bess et al. (2010) used ion 
exchange resin (Amberlite) to formulate taste masked dextromethorphan ODF. 
 
2.1.1(g) Inclusion complexation  
Cyclodextrins have been proposed as a taste masking agent in orally disintegrating 
dosage forms. Inclusion complexation is a process in which the drug molecule fits 
into the cavity of cyclodextrin. Cyclodextrin is capable of masking the bitter taste 
of the drug by decreasing the number of drug particles exposed to the taste buds, 
thereby reducing the perception of bitter taste (Nilesh et al., 2012).  
 
2.1.1(h) Adsorption 
Adsorbates can be used as taste masking agent. Drug solution can be mixed with 
an insoluble substrate that adsorbs on the surface of the drug particles when the 
solvent is removed. Substrates like Veegum® , bentonite, silica gel and silicates 




Sodium alginate has the ability to form water insoluble gelation on the surface of 
tablet in the presence of bivalent metal ions and can be used for taste masking of 
bitter drug. Tablet of amiprolose hydrochloride has been taste masked by applying 
an undercoat of sodium alginate and overcoat of calcium gluconate. In the 
presence of saliva, sodium alginate reacted with bivalent calcium to form a water 




2.1.1(j) Effervescent agents 
Effervescent agents, mixtures of sodium bicarbonate and organic acids, can be 
used as taste masking agents for solid dosage forms. The formulation contains the 
drug in combination with effervescent agent to promote their absorption in the 
oral cavity and to mask their bitter taste (Pather et al., 2002). 
 
2.2 Challenges in development of ODT 
Developing and manufacturing of ODT has never been an easy task. Habib et al. 
(2000) listed some potential challenges in developing ODT formulations. 
 
2.2.1 Mechanical strength and disintegration time 
ODTs are made of either very porous tablet structure or compressed into tablets 
with very low compression force for rapid disintegration in the oral cavity. As a 
result, the ODTs are friable, brittle, difficult to handle, and often require 
specialized peel-off blister pack to protect the product. Such fragile tablets tend to 
break during packing, transporting or handling by patients. Increasing the 
mechanical strength could adversely delay the disintegration time of the ODTs.  
 
2.2.2 Palatability and taste masking 
Many drugs are bitter in taste. It is not acceptable if ODT disintegrates and the 
bitter drugs dissolve in saliva to leave a bad taste. Poor taste will seriously affect 
patient compliance and acceptance of the dosage form. Effective taste masking 
technique which can mask the bitter taste of the drugs must be used so that the 
taste of the drug is not felt in the oral cavity. ODT with good taste increases the 
acceptance of patients and hence resolves the non-compliance issue. Mouthfeel is 
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another critical factor which affects the acceptance of the dosage form. ODT 
which disintegrates into larger particles in the oral cavity leave a poor mouthfeel 
on the tongue. The particles generated after disintegration of the ODT should be 
as small as possible. The addition of flavours and cooling agents, such as menthol, 
improves the mouth feel. 
 
2.2.3 Physical stability 
Most of the ODTs are hygroscopic in nature due to the ingredient used in the 
formulation and cannot maintain physical integrity under normal condition of 
temperature and relative humidity. Hence, special packaging is needed to protect 
the product from humidity.  
 
2.2.4 Cost of production 
ODT that is packed in specialized packaging increases the production cost. 
Similarly, ODTs for example, Zydis and Orasolv, that require special technologies 
and equipment, increase the cost of production to a remarkable extent (Habib et 
al., 2000). 
 
2.2.5 Drug loading 
The drug loading capacity determines whether a dosage form is practical. High 
drug loading capacity is generally desired. Incorporation of high dose of drug in 
ODT is very challenging as it can adversely affect the physical property of ODT 
especially the disintegration time. For lyophilized dosage forms, the dose should 
be less than 400 mg for insoluble drugs and less than 60 mg for soluble drugs 
(Ghosh and Pfister, 2005).  
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2.3 Approaches in ODT development 
ODT development employs one of the following approaches to achieve fast 
disintegration: maximizing the porous structure of the tablet matrix, incorporating 
appropriate disintegrating agent or using highly water-soluble excipients in the 
formulation (Kaur et al., 2011). 
 
2.3.1 Freeze-drying 
This method is suitable for thermolabile drugs since it does not employ heat in the 
manufacturing process. It is a process in which water is sublimated from the 
product after freezing. In this method, the active ingredient is first dissolved or 
dispersed in a polymeric / carrier solution. The solution / dispersion is then casted 
by weight into blister packs / moulds. The trays holding the blister packs / moulds 
are stored in freezer for freezing and the freeze drying process is continued with a 
freeze dryer. Finally, the blisters are packaged and shipped. The product prepared 
using this method is highly porous and has a very high specific surface area, 
which dissolves rapidly when in contact with water (Makino et al., 1996; Seager, 
1998; Reddy et al., 2002). The disadvantages of this method besides fragile 
product, are the high cost of equipment and complex processing steps (Kaur et al., 









2.3.2 Tablet moulding 
Tablet moulding method uses water-soluble ingredients so that the tablets dissolve 
completely and rapidly. Moulding process includes moistening, dissolving, or 
dispersing of drug with a solvent. The powder blend is then moulded into tablets 
under pressure lower than that used in conventional tablet compression. Air 
drying process removes the solvent in the tablet. As a result, moulded tablets are 
very porous and less compact than compressed tablets. The ODT possesses porous 
structure that improves dissolution (Dobetti, 2001; Reddy et al., 2002). However, 
the low hardness of the moulded tablets might be the limitation of this technique. 
Therefore, binding agents are required as part of the formulation to increase the 
mechanical strength of the tablets. Masaki and Ban (1995) reported the use of agar 
solution as binding agent in the preparation of an intrabuccally fast disintegrating 
tablet. This method is more practical to scale up for industrial manufacture than 






Sublimation is a manufacturing method which produces porous ODT with fast 
disintegration. Inert solid ingredients that volatilize readily (e.g. urea, ammonium 
carbonate, ammonium bicarbonate and camphor) are mixed with other tablet 
ingredients and the mixture is compressed into tablets. The volatile materials were 
then removed through sublimation by heat, producing ODT with porous structure 
(Makino et al., 1996). Koizumi et al. (1997) developed ODT using camphor as 
subliming material. Camphor was sublimated in vacuum at 800C for 30 min after 
preparation of ODT tablets. The ODTs produced disintegrated within 15 sec. 
 
2.3.4 Spray drying 
Allen and Wang (1996) reported a process for making a particulate support matrix 
for producing a rapidly dissolving tablet. Hydrolyzed and non-hydrolyzed gelatin 
were used as supporting matrix, mannitol as bulking agent, sodium starch 
glycolate as superdisintegrant, citric acid as buffering agent, water and ethanol as 
solvent system. The composition was introduced into the spray drying chamber. 
The particle formed from the droplet retained a high porosity and low density. The 
particulate support matrix could then be mixed with drug, flavouring agent, and a 
small amount of effervescent material (optional) to produce a rapidly dissolving 
tablet by one of the manufacturing methods such as direct compression.     
 
2.3.5 Mass extrusion 
Mass extrusion involves softening of the active blend using a solvent mixture of 
water-soluble polyethylene glycol and methanol, subsequent expulsion of 
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softened mass through the extruder into well-formed cylindrical extrudates, and 
cut into even segment using heating blade (Reddy et al., 2002). 
 
2.3.6 Compression-phase transition technique 
Kuno et al. (2008) introduced compression-phase transition technique to produce 
ODTs. This method was dependent upon the melting point of sugar alcohols. The 
process involved compressing the powder containing two sugar alcohols of high 
and low melting points and subsequently heating the compressed mass at the 
temperature between their melting points. Before the heating process, tablet did 
not have sufficient hardness because of the low compactability. However, tablet 
hardness was found to increase after heating due to diffusion and solidification of 
sugar alcohols (Kuno et al., 2008).  
 
2.3.7 Direct compression technique 
Direct compression is the easiest and conventional way to manufacture ODT. The 
advantages of this method are low manufacturing cost, the use of conventional 
equipment and a few processing steps. However, the disintegration and 
dissolution of the ODT are slower due to the more compacted and less porous 
ODT formed. The disintegration of ODT manufactured using this method relied 
on superdisintegrant, water soluble excipients and effervescent agents (Makino et 
al., 1996; Reddy et al., 2002). 
 
The survey conducted by Shangraw and Damarest (1993) showed that direct 
compression was the most preferred tablet manufacturing method compared to 
wet granulation and roller compaction. About 41% of the surveyed companies 
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responded that direct compression was the method of choice, 41.1% indicated that 
they used both direct compression and wet granulation method. Only 1.7% 
indicated that they never used direct compression method and 15.5% indicated 
that the process was not recommended.  
 
This method is simple and rapid compared to the more complicated and long 
process involved in the manufacture of tablets by wet granulation and roller 
compaction (Shangraw, 1989). It requires less equipment, lower power 
consumption, less space, less time and less labour leading to reduced production 
cost. Moreover, this method is suitable for moisture and heat sensitive APIs since 
the method does not involve wetting and drying of ingredients (Patel and Bhavsar, 
2009).  
 
However, the limitation is that not every single pharmaceutical excipient is 
suitable for direct compression. It has been estimated that less than 20% of 
pharmaceutical materials have high compressibility and can be compressed 
directly into tablets (Shangraw, 1989). Most of the pharmaceutical excipients lack 
the flow, cohesion or lubricating properties necessary for the production of tablets 
by direct compression. Weight variation and content uniformity problems might 
occur if the materials used lack of flowability.   
 
2.3.8 Nanocrystal technology 
The main principle behind nanocrystal technology is reduction of the particle size 
which results in increase of surface area, which in turn leads to an increase in 
dissolution. Nanocrystal colloidal dispersions of drug substance are combined 
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with water-soluble GRAS (Generally Regarded as Safe) ingredients 
(http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/) filled into 
blisters and lyophilized. The resultant ODTs are remarkably robust and can 
dissolve in a very small quantity of water within seconds. This technique is 
especially suitable for production of highly potent or hazardous drug products 
because it removes the need for some manufacturing operations such as 
granulation, blending, and tableting, which might generate large quantities of 
aerosolized powder and present higher risk of exposure (Hirani et al., 2009).  
 
2.3.9 Cotton candy process-compression 
This process utilizes a unique spinning mechanism to produce floss-like crystalline 
structure. Cotton candy process involves formation of matrix of polysaccharides or 
saccharides by simultaneous action of flash melting and spinning. The matrix formed 
is partially recrystallized to improve flow property and compressibility. This candy 
floss matrix is then milled and blended with active ingredients and excipients and 
subsequent compressed to orally disintegrating tablet. This process can accommodate 
larger drug doses and offers improved mechanical strength (Chiver and Minn, 1972).  
 
2.4 Examples of patented ODT technologies 
2.4.1 Zydis®  
Zydis®  is one of the oldest and best known technologies which use freeze-drying 
process to prepare ODT (Virely and Yarhood, 1989; Konar and Mukhopadhyay, 
2014). The tablet dissolves in the mouth within seconds after placement on the 
tongue due to the highly porous structure of the tablet. As Zydis®  dosage form is 
weak in physical strength, the tablet is contained in peelable blister pack, which 
allows product removal without damage (Ahmed et al., 2006). 
21 
 
2.4.2 OraSolv®  
CIMA Labs patented OraSolv®  as its first ODT technology. OraSolv®  uses 
effervescent principles to prepare ODT. The ODT contains effervescent material 
as disintegrating agent. The active ingredient is taste-masked beforehand. The 
ODT disintegrates very fast when the effervescent material dissolves in saliva. 
Carbon dioxide is generated by a reaction of the formulation components upon 
exposure to saliva in the mouth. Tablets are made by direct compression technique 
at low compression force to minimize oral dissolution time. OraSolv®  usually 
dissolves in the oral cavity within 15 s to 3 min. Due to the low mechanical 
strength property, the ODT produced are soft and friable and packaged in 
specially designed pack (Tagaki et al., 2007). 
 
2.4.3 DuraSolv®  
CIMA Labs patented DuraSolv®  as its second ODT technology. DuraSolv 
technology showed improvement in mechanical strength, which is the major 
limitation of Orasolv® . The DuraSolv®  technology has a formulation similar to the 
OraSolv®  technology, combining taste masked drug particles with or without a 
low amount of effervescent agent containing formulation. The tablets made by 
this technology consist of drug, fillers and a lubricant. Tablets are prepared using 
conventional tableting equipment and have good rigidity. Durasolv®  technology 
has been developed for drug strengths in the range of 125 µg – 500 mg with 
disintegration times designed in the range of 10 to 50 seconds. With DuraSolv®  
technology, tablets are compressed to a greater hardness of 15 – 100 N, resulting 
in a more durable ODT. Durasolv®  product is very robust and can be packed in 
traditional blister pack (Cirri et al., 2005).  
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2.4.4 Wowtab®  technology 
Wowtab®  technology was patented by Yamanouchi Pharmaceutical Co (Fu et al., 
2004). This technology utilizes sugar and sugar-like excipients. Two different 
types of saccharides are combined to produce fast dissolving tablets using 
conventional granulation and tableting technique. According to the patent, 
saccharides were divided into two groups, high mouldability and low 
mouldability. The low mouldability saccharides produced tablets with hardness 
between 0-2 kg when 150 mg of such saccharide was compressed under pressure 
of 10-50 kg/cm using a die of 8 mm in diameter. The typical low mouldability 
saccharides include lactose, mannitol, glucose, sucrose and xylitol for rapid 
dissolution. High mouldability saccharides produce tablets with hardness above 2 
kg when prepared under identical conditions. The typical high mouldability 
saccharides are maltose, maltitol, sorbitol and oligosaccharides for good binding 
property. Saccharides having low mouldability were granulated with saccharides 
having high mouldability. The low mouldability saccharides were used as the 
main component. The Wowtab®  formulation is more stable than Zydis®  and 
OraSolv® . 
 
2.4.5 PharmaburstTM 500 
SPI Pharma patented its ODT technology called PharmaburstTM 500 (Kathpalia 
and Jogi, 2014). It utilizes co-processed excipients to develop ODT, which 
dissolves within 30-40 s. PharmaburstTM 500 is a co-processed excipient which 
consists of mannitol, sorbitol, crospovidone, silica, aspartame and magnesium 
stearate.  PharmaburstTM 500 is a ready to use system which has been specifically 
engineered to manufacture robust, rapidly disintegrating ODTs with superior 
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organoleptic properties. PharmaburstTM 500 can be used on standard tableting 
equipment to formulate tablets with up to 500 mg active ingredient.  
 
2.4.6 NanomeltTM 
NanomeltTM employs nanocrystal technology to manufacture ODT.  It was 
patented by Elan Corporation. Nanosized particles increases the surface area, 
which leads to a faster disintegration rate of tablet and an increase in dissolution 
rate. NanoCrystalTM particles are ultra-small particles which are typically less than 
1000 nm in diameter. They are produced by milling the drug substance using a 
proprietary wet milling technique. Badgujar and Mundada (2011) provided the 
benefits of this technology which are given below: 
a. Pharmacokinetic benefits of orally administered nanoparticles (less 
than 2 microns) in the form of a rapidly disintegrating tablet matrix. 
b. Product differentiation based upon a combination of proprietary and 
patent-protected technology elements 
c. Exceptional durability, enabling use of conventional packaging 
equipment and formats 
d. Wide range of doses (up to 200 mg of active pharmaceutical ingredient 
per unit) 
e. Use of conventional, compendia inactive components 
f. Employment of non-moisture sensitive excipient   
 
2.4.7 Flashdose®  technology 
Flashdose®  technology was invented by Fuisz Technologies, USA. This 
technology utilizes the concept of cotton candy process. Fuisz Technologies has 
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developed three oral drug delivery systems that involve fast dissolution. The first 
two generations are quick-dissolving Soft Chew and EZ Chew tablets which 
require some chewing. Flashdose®  technology is the third generation technology 
which uses a unique spinning mechanism to produce a flash-like crystalline 
structure, much like cotton candy. APIs can be mixed with these crystalline sugars 
and compressed into tablets. The floss cotton candy-like fibers are made up of 
saccharides such as sucrose, dextrose, lactose and fructose. Sucrose requires a 
temperature of 82–130 °C to be transformed into fibers while other 
polysaccharides such as polymaltodextrins and polydextrose require 30–40 % 
lower temperature than sucrose. The Flashdose®  manufacturing process can be 
divided into four steps, (i) floss blend, (ii) floss processing, (iii) floss chopping 
and conditioning and (iv) tablet blend and compression (Fuisz, 1997; Badgujar 
and Mundada, 2011). 
 
2.4.8 Flashtab®  
Flashtab®  technology was developed by Prographarm. In this technology, the 
disintegration depends on the combination of a disintegrating agent and a swelling 
agent. The coated taste-masked drug is blended with disintegrating agent and 
swelling agent by wet or dry granulation method followed by compression into 
tablets. The product is a compacted tablet with fast disintegration property. The 
packaging material is usually blister packed using high quality polyvinyl chloride 
or aluminum foil for providing a higher degree of moisture protection (Wagh et 
al., 2010). 
 
 
